What was Shaily Engineering Plastics's revenue in Q3 FY26?

Shaily Engineering Plastics reported revenue of ₹251 Cr in Q3 FY26, a +27% change year-over-year.

Did Shaily Engineering Plastics management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

SHAILYENGINEERINGPLASTIC Diversified 10 Feb 2026

Shaily Engineering Plastics Ltd — Q3 FY26

Q: What guidance did Shaily Engineering Plastics management give?

FY26 pen injector volume guidance of ~30M units maintained: Management retains ~30M pen injector volume guidance for FY26, though slightly lower due to 3-month qualification delays on high-speed lines.

Shaily Engineering delivered a strong Q3 FY26 with revenue of ₹251 crore (+27% YoY) and EBITDA of ₹66 crore (+43% YoY), driven by healthcare segment revenue doubling to ₹104 crore (42% of mix).

Revenue ₹251 Cr +27%

EBITDA ₹66 Cr +43%

PAT ₹37 Cr +48%

EBITDA Margin 26.5% +310bps

Duration 76 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Shaily Engineering delivered a strong Q3 FY26 with revenue of ₹251 crore (+27% YoY) and EBITDA of ₹66 crore (+43% YoY), driven by healthcare segment revenue doubling to ₹104 crore (42% of mix). EBITDA margin expanded 310 bps to 26.5%, though consolidated margins were temporarily impacted by delayed milestone income from UK/UAE operations. Healthcare growth was fueled by GLP-1 pen injector supplies for commercial launches in Canada, Brazil, India, and other markets. Management announced a new Abu Dhabi facility (₹300-350 crore capex, 75M unit capacity, operational by Q4 FY28) to meet surging demand, with 50-60% capacity already backed by take-or-pay contracts. Consumer segment declined 13% YoY due to weak European demand. Key risk: delays in qualifying high-speed pen assembly lines could constrain near-term revenue ramp-up.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

!Risks 4 risks

Risk Intelligence

High-speed line qualification delays

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Healthcare segment revenue ₹104 Cr

+139% YoY

Healthcare revenue doubled to 42% of total mix, driven by GLP-1 pen injector supplies.

Pen injector capacity (India) 80M units

+50M units YoY

Two new 25M lines being added; first line under qualification, second arriving Apr-May 2026.

Polymer processed (Q3) 5,541 tons

-12% YoY

Decline due to consumer segment slowdown; 9-month volume up 4.4% YoY.

Export share 71%

Flat YoY

Exports remained strong at 71% of total revenue in both Q3 and 9M FY26.

Fast read

Guidance and risk preview

Top guidance FY26 pen injector volume guidance of ~30M units maintained

Management retains ~30M pen injector volume guidance for FY26, though slightly lower due to 3-month qualification delays on high-speed lines.

Top risk High-speed line qualification delays

First 25M pen line qualification delayed from Oct 2025 to Feb 2026 due to complexity; second line may face similar issues, impacting near-term reve...

View Risks →